Calvin Chin
Managing Partner @ E14 Fund
San Francisco, United States
Calvin Chin is a angel investor at E14 Fund in San Francisco focused on Genetics and Software. Calvin was previously founder and CEO of Qifang, China’s first online student loan service and the first Chinese company recognized by the World Economic Forum as a Technology Pioneer.Calvin is a member of the Aspen Institute’s inaugural China Fellowship Program, a WEF Young Global Leader and served on the WEF Global Agenda Council on SocialInnovation.He was named one of Fast Company magazine’s 100 Most Creative People In Business for 2011, was named 2009 Chinese Business Leader of the Year by Horasis and Baker & McKenzie, and is a Social Innovation Park Fellow.He has an MBA from TRIUM (NYU, LSE, HEC Paris), a B.A. from Yale University and has also studied social entrepreneurship, global leadership and other management and policy subjects at Harvard University and INSEAD.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Calvin Chin invests in
Stages Calvin Chin invests in
Countries Calvin Chin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Genetics 2 (25%)
- Software 2 (25%)
- Biotechnology 2 (25%)
- Nanotechnology 2 (25%)
- GPU 1 (13%)
Stage
- Angel 2 (25%)
- Pre-Seed 2 (25%)
- Series A 2 (25%)
- Seed 1 (13%)
- Funding Round 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Respira Labs is developing the first wearable device to measure “trapped air,” an early marker of Chronic Obstructive Pulmonary Disease (COPD). No reliable and validated methods currently exist to detect COPD exacerbations in time for early intervention and prevention. By leveraging the power of non-invasive acoustic sensors, audio signalprocessing, machine learning and Acoustic Resonance Index Analysis (ARIA), our device will fundamentally revolutionize COPD management by predicting and preventing attacks at the patient’s home, significantly improving health outcomes and patient quality of life while dramatically lowering health care costs. | $50K / Feb 20, 2024 | ||
| Brelyon is a developer of a display used to replace traditional monitors and virtual reality headgears. It was founded in 2019 and is headquartered in San Mateo, California. | $16.2M / Series A / May 11, 2022 | ||
| Sourcemap develops enterprise software for end-to-end supply chain visibility. It provides a full-suite solution for supply chain transparency and traceability. It includes end-to-end supply chain due diligence, customs compliance, environmental and social sustainability, business continuity, and operations planning. | $10M / Series A / Mar 01, 2022 | ||
| ThruWave produces millimeter wave imaging technology designed for markets including robotics, construction, and quality control. The company's low-cost sensors for commercial and industrial applications use patent-pending radar signal processing innovations and GPU accelerated image reconstruction techniques. Its technology lowers risk byimaging the internal structure of walls, ceilings, and floors that enable construction professionals to work faster.ThruWave was founded in 2017 and is headquartered in Seattle, Washington. | $6.4M / Seed / Sep 03, 2020 | ||
| Brelyon is a developer of a display used to replace traditional monitors and virtual reality headgears. It was founded in 2019 and is headquartered in San Mateo, California. | $1.6M / Pre-Seed / Jul 15, 2020 | ||
| Homestead is powering the transition to a new type of homeownership. It is opening up new opportunities for affordable housing throughout California, effectively turning every homeowner into a developer.In exchange for the use of their backyard, its products provide existing homeowners with $250k-$1.5M in income to build new homes that sell for25% less than the market average. | $1.7M / Pre-Seed / May 13, 2020 | ||
| Ligandal's mission is to create personalized gene therapies to cure disease. We are driving the discovery and delivery of a broad array of gene therapies, genetic materials, and gene-specific payloads with unprecedented precision at the cellular and sub-cellular level. Our ligand discovery engine allows for rapid design ofdiagnostically-responsive materials, capable of shuttling a variety of nucleic acid and protein payloads (including CRISPR and mRNA) to specific cell types. We are initially applying this technology to gene editing indications in hematology and immuno-oncology. | $250K / Angel / Jan 01, 2015 | ||
| Ligandal's mission is to create precision delivery platform to cure and treat disease. We are driving the discovery and delivery of a broad array of gene therapies, genetic materials, and gene-specific payloads with unprecedented precision at the cellular and sub-cellular level. Our ligand discovery engine allows for rapid design ofdiagnostically-responsive materials, capable of shuttling a variety of nucleic acid and protein payloads (including CRISPR and mRNA) to specific cell types. We are initially applying this technology to indications in hematology, immuno-oncology, and infectious disease. | $250K / Angel / Jan 01, 2015 |
Co-Investors
About E14 Fund
E14 Fund are an investment fund focused on taking the biggest ideas hatched at MIT, deploying them to the real world, and scaling them for greatest impact. At the E14 Fund, they help bring technologies out of the lab and into the world. Their network of advisors—investors, industry experts, and entrepreneurs—help their companies take prototypes to scale and raise further investment. The E14 Fund supports companies across diverse fields—from biotechnology and smart cities to consumer electronics and manufacturing. They are a bridge that builds entrepreneurs from MIT and creates the paths to connect them with investors and industry experts who can help them scale. They believe diversity and inclusion are the seeds of innovation. Half of their companies have a female founder, and more than half have founders are from outside the United States.
E14 Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Calvin Chin
Managing Partner
|
|||
David Cranor
Venture Partner
|
|||
Habib Haddad
Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Calvin Chin invest in?
Calvin Chin invests primarily in Genetics, Software and Biotechnology startups, most often at Angel and Pre-Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Calvin Chin?
Public channels for Calvin Chin include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Calvin Chin last invest?
The most recent investment recorded for Calvin Chin closed in Feb 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
